Associations of Plasma-Soluble Fas Ligand with Aging and Age-Related Macular Degeneration

To evaluate the associations between plasma-soluble Fas ligand (sFasL) and age-related macular degeneration (AMD). Plasma samples were obtained from 230 individuals (age range, 45-85), with or without AMD. The concentrations of sFasL were determined by an enzyme-linked immunosorbent assay (ELISA). T...

Full description

Saved in:
Bibliographic Details
Published in:Investigative ophthalmology & visual science 2008-04, Vol.49 (4), p.1345-1349
Main Authors: Jiang, Shunai, Moriarty-Craige, Siobhan E, Li, Chun, Lynn, Michael J, Cai, Jiyang, Jones, Dean P, Sternberg, Paul
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Aging - physiology
Biological and medical sciences
Enzyme-Linked Immunosorbent Assay
Eye and associated structures. Visual pathways and centers. Vision
Fas Ligand Protein - blood
Female
Fundamental and applied biological sciences. Psychology
Humans
Macular Degeneration - blood
Male
Medical sciences
Middle Aged
Ophthalmology
Retinopathies
Vertebrates: nervous system and sense organs
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the associations between plasma-soluble Fas ligand (sFasL) and age-related macular degeneration (AMD). Plasma samples were obtained from 230 individuals (age range, 45-85), with or without AMD. The concentrations of sFasL were determined by an enzyme-linked immunosorbent assay (ELISA). The measured sFasL levels were transformed into cubic roots and were fitted into linear regression models against AMD status, with adjustment for age and sex. Plasma sFasL increased with age and AMD. There was a linear correlation between age and the cubic roots of sFasL. The plasma sFasL concentrations in non-AMD subjects ranged from 0 to 1.63 ng/mL (median, 0.69 ng/mL), whereas in patients with AMD, sFasL ranged from 0 to 2.43 ng/mL (median, 0.18 ng/mL). Between the ages of 61 and 84, the subjects with AMD had significantly higher sFasL than did the non-AMD subjects. There was a sexual dimorphism of the plasma sFasL levels. In non-AMD subjects, sFasL was lower in the females. In patients with AMD, sFasL was higher in the females. An elevation of plasma sFasL with aging may play a role in the development of AMD and is a potential peripheral marker for monitoring disease progression.
ISSN:0146-0404
1552-5783
1552-5783
DOI:10.1167/iovs.07-0308